Amyris

Loading quotes...

Forecast

Buy	9
Hold	9
Sell	2

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last year, Amyris had revenue of €251.57m and net profit of -€499.62m

(EUR)	2022	YoY
Revenue	251.57m	16.31%
Gross profit	10.42m	93.65%
Net profit	-499.62m	115.04%
EBITDA	-453.65m	120.44%

Fundamentals

Metric	Value
Market capitalization	€0
52-week high/low	€0.0577 - €0.0449
Dividends	No
Beta	1.19
P/E ratio	-0.03
PEG ratio	0.00
P/B ratio	-0.04
P/S ratio	0.00

Company profile

Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. It offers its products under the Biossance, Pipette, Purecane, Terasana, Costa Brazil, OLIKA, Rose Inc., and JVN brand names. The company has a collaboration agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California.